OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2022-03-31-accounts

cancer 52 the common voice for rare & less common cancers

Cancer52 is registered as a charity in England and Wales, Charity No. 1174569 and as a company limited by guarantee in England and Wales, Company No. 07994413

Annual Review & Financial Statements 1 Apr 2021 – 31 Mar 2022

cancer52.org.uk

Contents

Contents
WELCOME: TRUSTEES ANNUAL REPORT
AND DIRECTORS REPORT FOR THE YEAR
ENDED 31ST MARCH 2022 3
Foreword 3
Welcome to our Annual Review 2021–2022 3
STRENGTH IN UNITY: OUR PRINCIPLES 4
Our core principles 4
UNITING WITH ONE VOICE:
WHO WE ARE 5
TheCancer52team 5
Our charity members 5
The Impact of Covid-19 5
MAKING THE CANCER52 VOICE
HEARD 6
Informing, advising and supporting
our members 6
PARTNERSHIP: REPRESENTATION
AND ADVOCACY IN POLICY 8
PARTNERSHIP: COLLABORATION
ON BEHALF OF THE PATIENTS
Informing our stakeholders		 10
12
WELCOME: TRUSTEES ANNUAL REPORT FUNDING 14
AND DIRECTORS REPORT FOR THE YEAR The value of our support 14
ENDED 31ST MARCH 2022 3 Voluntary member donations 14
Foreword 3 Support from industry 14
Welcome to our Annual Review 2021–2022 3
FUTURE PLANS 15
STRENGTH IN UNITY: OUR PRINCIPLES 4
Our core principles 4 THE ACOUSTICS:
STRUCTURE AND CONSTITUTION 16
UNITING WITH ONE VOICE: Structure and governance 16
WHO WE ARE 5 Purpose 16
TheCancer52team 5 Public beneft 16
Our charity members 5 Board and management operations and
The Impact of Covid-19 5 structure 17
MAKING THE CANCER52 VOICE
HEARD 6 MONEY TALKS: FINANCIAL REVIEW
Informing, advising and supporting 2020–2021 19
our members 6
INDEPENDENT EXAMINERS’ REPORT
PARTNERSHIP: REPRESENTATION TO THE TRUSTEES OF CANCER52 20
AND ADVOCACY IN POLICY 8 Independent examiner’s report to the
trustees of Cancer52 20
PARTNERSHIP: COLLABORATION Section A 22
ON BEHALF OF THE PATIENTS
Informing our stakeholders		 10
12		 Section B 23
Section C 24
MAKING THE VOICE OF PEOPLE
WITH RARE AND LESS COMMON
CANCERS HEARD: OUR HEADLINE ADMINISTRATIVE DETAILS 35
ACHIEVEMENTS FOR 2021–2022 13
Partnership 13 REFERENCES 36
Policy 13
Patients 13 LIST OF CHARITY MEMBERS 2020–2021 37

Welcome:

Trustees Annual Report and Directors Report for the year ended 31st March 2022

Foreword

The year 2022 marks my seventh and final year as Chair of Cancer52 . As I look back, I’ve been proud to witness the organisation grow in stature. It successfully built on its core remit, to advance collaborative policy leadership for the rare and less common cancer community, all while maintaining steadfast support for its members, enabling them to navigate challenges together, including a health system and Government still in the throes of dealing with the COVID-19 pandemic.

Laying this groundwork means Cancer52 is ready for an exciting future of further expansion and widening influence.

Jonathan Pearce, Chair

Welcome to our Annual Review 2021-22

We are delighted to welcome readers to this Annual Review, which covers the year to the end of March 2022.

It has been a challenging year but we have grown our membership and our influence and worked with a widening group of stakeholders to deliver ever more ambitious projects. All of this could only have been achieved with our small but dedicated and committed team, and my thanks to them.

And now – as the world opens up again to human rather than technological interaction – our opportunities to network and share our aims and values are growing. With the help of our many partners we will continue to deliver on projects and activities that help build the voice of the hundreds of thousands of people with a rare or less common cancer.

Jane Lyons, CEO

My thanks to Jonathan for his ongoing support over the years. We will miss him as chair but are delighted that he will stay on as a trustee.

Finally huge thanks to all those working within the NHS to support people with a rare or less common cancer. We salute your dedication, knowledge, and work ethic.

cancer52.org.uk 3

Strength in unity: our principles

Cancer52 is a national organisation, created in 2007 by Professor Sir Mike Richards, CBE, then National Cancer Director, and was registered as a charity in England and Wales in September 2017.

We are a unifying body for charitable and not-for-profit organisations working in the field of rare and less common cancers. We represent well over 100, predominantly small, patient-support and research-focused cancer charities and organisations.

Cancer52 gets its name from when rare and less common cancers accounted for 52% of all cancer deaths in the UK, despite the fact that only 47% of cancers diagnosed in England are of this type.[1] In 2020, this shifted to 47% of diagnoses yet 55% of cancer deaths.[2]

Our member charities and organisations are united in seeking a better future for everyone affected by rare and less common cancers. We provide a collective voice to champion earlier diagnosis, better treatment, better representation, funding and support for people with cancers other than the four most common cancers (breast, lung, bowel and prostate). Cancer52 ensures the voice of people with rare and less common cancers does not go unheard.

----- Start of picture text -----
47%
of cancers
diagnosed are rare
and less common
cancers
55%
of all cancer deaths
are caused by rare
and less common
cancers
----- End of picture text -----

Our core principles

Our aim

Our primary aim is to promote improved diagnosis, treatment and support for those affected by rare and less common cancers.

Our mission

Our mission is to provide a strong, unified voice for rare and less common cancer organisations by representing, speaking, informing, sharing and involving our members in achieving our vision.

Our vision

Our vision is to see an end to the inequalities in diagnosis, treatment and patient outcomes experienced by those with these challenging diseases compared with the four most common cancers.

Our values

Everything we do is underpinned by our values, which are to be:

ambitious | outcomes-focused | collaborative | evidence-based | influential and to behave with honesty and integrity.

4

Uniting with one voice: who we are

Cancer52 aims to better represent people with rare and less common cancers at a senior policy and decision-making level. Sourcing and bringing together the knowledge and expertise of our many members makes this possible.

The Cancer52 team

During the year ending 31 March 2022, the core team consisted of:

Our Board of Trustees is listed on page 35.

Consultants, Laura Thomas and Jennifer Mitchell, from Brighter Together Consulting worked with us on policy and Jason Dennis ran our finances.

Thanks to you all for your hard work and dedication.

Our charity members

Our members are united in their determination to improve treatment and outcomes for their individual patient groups.

They are mostly small but fiercely dedicated organisations that offer patient support, often with a research focus.

The vast majority (75%) of our membership have an annual income of less than £1 million, with 67% on an income of less than £500,000 and 38% with an income of less than £100,000. Almost all our members offer patient support and over two-thirds invest in research.[3]

The full list of Cancer52’s members for the financial year 2021-22, can be seen on page 37.

Our active membership continues to grow, and during the financial year 2021-22, 10 new charities of varying sizes joined Cancer52. We happily welcomed: Live Through This, Leukaemia UK, North West Cancer Research, Paul’s Cancer Support Centre, Penny Brohn UK, The Charley Ashton Foundation, The Myrovlytis Trust, The Urology Foundation, ThymicUK, and Wendy Gough Cancer Awareness Foundation .

We hugely value and appreciate our members’ ongoing dedication and commitment to Cancer52 .

The impact of Covid-19

Despite Covid-19’s continued impact we maintained a high level of engagement with our members and their patient groups during the slow return to normal.

We are proud of our ongoing learning and how we have adapted to deeply challenging and complex circumstances across the health system, especially when Covid relief funds were wound down.

Helping members keep patients informed

While we join others in welcoming the gradual return to new normal, our focus remains on the threat of infection for patients who are immunosuppressed.

Cancer52 , among other charities, supported the Deputy Chief Medical Officer (DMCO) and Department of Health and Social Care (DHSC) in England to cascade critical information to the public. We knew that shielding was a key issue for those living with cancer so joined the DHSC Shielding Advisory Group meetings to help share salient information on any changes in shielding advice.

cancer52.org.uk 5

Making the Cancer52 voice heard

We work tirelessly to support people with rare and less common cancers and to ensure we have a strong presence in the rare and less common cancer community.

From telephone conversations and surveys to seats on influential national cancer bodies, we take every opportunity to represent people with rare and less common cancers.

Informing, advising and supporting our members

Regular e-bulletins kept our members informed and bimonthly virtual meetings offered a chance to voice any questions and concerns and communicate shared learnings. New monthly virtual CEO Meetings linked together CEOs on higher level activities.

Meeting with our members

Our virtual meetings remain in place, as over the year they empowered charities from across the country to connect, and quickly and easily share information.

376

individuals attending All Member Meetings

Sharing

We want everyone with rare and less common cancers to have the chance to be best supported and make informed choices. We consistently encourage our members to talk to each other and the resulting knowledge exchange means that even those supported by charities with limited resources have access to continuing flow of useful information.

Creating collaboration helps charities from duplicating effort and frees up resources to better support people with cancer. We know that a collaborative voice is a stronger voice.

‘I’m very impressed by everything that you’re doing at the moment – Cancer52 is certainly having a big impact and we are proud to be a member.’

Lydia Makaroff, CEO, Fight Bladder Cancer

Regular members’ e-bulletin

150+

attended one of our many working group meetings

200+

people attended our monthly CEO meetings

Throughout this financial year, our weekly or biweekly e-bulletin updated our members on:

6

We want everyone with rare and less common cancers to have the chance to be best supported and make informed choices.

The e-bulletins have an average 40% open rate and 8.3% click-through rate, which is significantly more than the industry average.[4] It shows members prize our bulletins as a useful and efficient way of disseminating information so that they and their patients are aware of critical events, activities and developments.

‘Thank you Cancer52 for your sterling work for the cause of the rare and less common cancer communities.’ Helen Morement, CEO, AMMF

CANCER52 ALL MEMBER MEETINGS

Fortnightly virtual meetings continued throughout the financial year. They offer ideal networking opportunities and the chance to help patients by learning from interesting and thought-provoking speakers. Meetings were warmly welcomed and well attended, most notably the launch of the “DoYouCUs?” Campaign, which attracted nearly 50 attendees.

The meetings are great relationship builders and boost the profile of people with rare and less common cancers.

CEO CALLS AND MEETINGS

Monthly video calls started in August 2020 and provide member CEOs direct access to their peers. These meetings have become incredibly valuable opportunities to raise problems, talk through ideas, share best practice or discuss ways of increasing awareness and boosting the sector’s profile.

‘Cancer52 has created our network, fab having peers we can reach. We have a real sense of community.’

Liz Darlison, CEO, Mesothelioma UK

WORKING GROUPS

Some of our members face similar challenges in supporting people with cancer so we set up additional working groups on specific shared areas. New groups examined cancerrelated menopause, health inequalities, IBS (by way of misdiagnosis), and the NHS website cancer pages.

cancer52.org.uk 7

Partnership: Representation and advocacy in policy

Cancer52 represents its members at the highest level and acts as a conduit to organisations that need to hear the patient voice of people with rare and less common cancers. As a strong and determined alliance, we can make more noise about the need for improvements in cancer services, including those supported by our member charities.

During 2021–2022, we were invited to sit on several NHS England (NHSE) boards and groups where we used our influence to oversee, advise on and implement the NHS Long Term Plan (LTP)[5] for cancer.

HEALTH AND SOCIAL CARE SELECT COMMITTEE

Cancer52 responded to two Health and Social Care Select Committee Inquiries: Cancer Services and Clearing the Backlog Caused by the Pandemic.[6] Cancer52’s CEO, Jane Lyons, contributed evidence at an oral hearing of the inquiry into cancer services. The resulting Health and Social Care Committee Report on Cancer services made key recommendations using Cancer52’s evidence, including recommending an action plan for rare and less common cancers.[7]

CANCER CHARITIES

Cancer52 also works collaboratively with many charities outside its direct membership where this has more impact for people living with cancer.

A key example of this is the One Cancer Voice (OCV) initiative where over 50 charities work together on fundamental policy asks such as investing in the workforce that helps people with cancer, and increasing spend on diagnostics. We sit on the steering group and instigated and provided the structure and pro bono time to develop the pan cancer charity

response to the Cancer Plan call for evidence in spring 2022.[8]

CANCER52 POLICY AND PUBLIC AFFAIRS STEERING GROUP

Our Policy and Public Affairs Steering Group (PPASG) met frequently to exchange information and help formulate Cancer52’s policy asks. They helped to inform our responses to the Cancer Plan call for evidence and Health and Social Care Select Committee inquiries. During 2020–2021 this group was chaired by Chris Walden, Cancer52 Trustee and Deputy Director of Policy, Campaigns and Engagement at Blood Cancer UK, with vice chair Bradley Price, Policy and Public Affairs Manager of Sarcoma UK. The discussions help develop Cancer52 policy.

CANCER52 NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) WORKING GROUP ACCESS TO MEDICINES WORKING GROUP

This group convenes whenever issues impact several Cancer52 members, most often looking at the role of patients in NICE processes and the ability to get the patient voice heard at NICE.[9]

8

10-YEAR CANCER PLAN

Early in 2022 we were invited to join a round table hosted by the then Secretary of State for Health and Social Care, the Rt Hon Sajid Javid MP, where he launched a call for evidence for his new 10-year plan for cancer.[10]

At time of writing the Plan is still being developed while ministerial appointments settle.

Cancer52 led the pan cancer charity collaboration, worked with members (including surveying members online) and other charities to help draft our own response and attended various evidence-gathering meetings hosted by the DHSC. To push views of people with rare and less common cancers into the spotlight we commissioned a patient survey and incorporated the findings from 259 patients into our response.[11]

259

We commissioned a patient survey and incorporated the findings from 259 patients into our response

----- Start of picture text -----
The Pan Cancer Charity Collaboration
----- End of picture text -----

cancer52.org.uk 9

Partnership: Collaboration on behalf of patients

MAKING THE VOICE OF PEOPLE WITH RARE AND LESS COMMON CANCERS HEARD

Working closely with the pharmaceutical company Pfizer, Cancer52 launched the awareness raising campaign Do You C Us? in the summer of 2021. A campaign website was created featuring facts and figures and patient videos.[12] The campaign was launched virtually at a parliamentary event hosted by Paul Bristow MP and joined by Cancer52 members and other MPs. The team also worked to secure press and social media coverage.

Working collaboratively across the NHS

WORKING WITH THE NHS CANCER PROGRAMME

NATIONAL CANCER BOARD

Alongside Cancer Research UK and Macmillan Cancer Support, we have a place on the NHSE National Cancer Board. Together we provide strategic leadership across the healthcare sector in the delivery of the cancer ambitions inside the NHS Long Term Plan.[5]

Cancer52 also holds a place on the following NHSE cancer programme groups:

NHSE’S HELP US, HELP YOU CAMPAIGN

Cancer52 helped ensure that the voice of people with rare and less common cancers were heard in this national cancer symptom awareness campaign. Cancer52 worked with partners in NHSE to drive interest amongst members and then facilitate their involvement. As a result, NHSE collaborated with the following Cancer52 members on the Clear on Cancer – Help Us, Help You national campaign to create co-branded stills and videos:

Cancer52 helped ensure that the voice of people with rare and less common cancers were heard in this national cancer symptom awareness campaign.

10

Working collaboratively across the wider cancer community

We also worked closely with a number of other organisations within the UK cancer community where it served the purpose of ensuring the voice of people with rare and less common cancers was better heard.

CHARITY MEDICINES ACCESS COALITION (CMAC)

Many people need quicker access to new and innovative medicines. This umbrella group of charities works to find a long-term solution to this problem. We are grateful to member charities for representing us on this Coalition.

CHILDREN AND YOUNG PEOPLE CANCER COALITION

Many of our member charities support children and young people with cancer and these charities have formed the Children and Young People Cancer Coalition. We sit on the steering group and support the work of charities in this field.

NATIONAL VOICES

This wide-ranging coalition of healthcare charities helps us engage where topics are particularly relevant to people with rare and less common cancers.

SPECIALISED HEALTHCARE ALLIANCE

This Alliance campaigns on behalf of those with rare and complex conditions. Cancer52 is a member and attends briefings on wider topics affecting people with rare cancers.

THE ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY

Our CEO sits on the newly formed ABPI Patient Advisory Council.

The ABPI holds quarterly meetings of its Patient Organisation Forum. We join the briefings alongside other charities and sit on the steering group that plans the meetings and organises speakers.

In February 2022, Cancer52 worked with the Association of the British Pharmaceutical Industry (ABPI) on an Anti-Microbial Resistance campaign specific to people living with rare and less common cancers called Together for Antibiotics.[13,14 ]

cancer52.org.uk 11

Informing our stakeholders

Collectively, and also as our member representatives, we are in ongoing communication with members of other charities, NHS professionals and administrators, and anyone who has influence in the rare and less common cancer field .

Cancer52 Annual Stakeholder Meetings

Our annual Stakeholder Meeting offers a great opportunity for all our members to engage with senior level speakers and industry representatives.

Due to the onoing COVID-19 pandemic the Annual All Stakeholder Meeting was held virtually in October 2021. The theme was Early Diagnosis, and it was attended by 75 delegates representing members, industry, the Government and NHS.

For the first time in two years, we plan to go back to an in-person event for October 2022.

Website

Our website acts as a central point for information and spreads the message that patient experience, treatment and outcomes will only improve with more time, money and effort focused on coping with rare and less common cancers.

The site includes links to all member organisations, plus the sponsors and groups we collaborate with to offer a useful portal for sharing information between members, patients, and the general public. We posted reports on our activities during the year and featured a news stream of prominent issues.

Website users can access reports together with informative videos, announcements of upcoming conferences or meetings, contact and donation opportunities.

Social media and media

We have been especially active during this year on Facebook and Twitter, gathering a total of 2,500 followers to date. We use our social media channels to distribute new information, react to events and communicate with our members. We excel at supporting member charities on Twitter by reposting their awareness campaigns and fundraising activities and facilitating engagement with patients. This can be especially effective to amplify awareness of a rare or less common type of cancer by tagging several members into a post to help create a unified voice for patients.

12

Making the voice of people with rare and less common cancers heard: our headline achievements for 2021–2022

We are proud of our achievements during what has been a challenging year for us, our members and the for the NHS.

Partnership

INFORMING, SHARING WITH, AND EMPOWERING OUR MEMBERS

We are grateful for the engagement and significant positive feedback from our members. This confirms that our redoubled efforts to improve our communications through our e-bulletins, All Member Meetings, CEO calls and meetings, group meetings, patient surveys, CEO survey and CEO briefings have been well received.

Our membership and engagement levels increased significantly.

Policy

RESPONDING COLLECTIVELY TO THE CHANGING POLITICAL CANCER PRIORITIES

We continue to work alongside NHSE Cancer Programme to improve outcomes for those with rare and less common cancers and to meet the early diagnosis target of diagnosing 75% of all cancers at stage I and II by 2028. We also worked collaboratively with our members and the wider cancer charity community to respond effectively to the Government’s 10-year Cancer Plan Call for Evidence.

Patients

ADVOCATING FOR THOSE AFFECTED BY RARE AND LESS COMMON CANCERS THROUGH COLLABORATION

We raise the profile of patients with a rare and less common cancer by consistently taking the patient voice to influencers and policy makers. We have a unique place in the cancer community and take every opportunity to make this patient voice heard.

cancer52.org.uk 13

Our support: sources of funding

In 2021–2022, we received funding from a variety of sources: donations from members; individual donations; and support from pharmaceutical companies.

The value of our support

We equally appreciate the valuable time, expertise and energy generously donated by our members.

We are hugely grateful to every donor and supporter for their financial support which helps propel us towards achieving our objectives. The financial benefaction of our charity members represents a very significant contribution in terms of the number and variety of organisations that support Cancer52 .

Voluntary member donations

The vast majority of our financial supporters are our member charities from whom we request a voluntary donation to our work that is aligned to their income. We aim to offer free membership to smaller charities with financial challenges although, in many cases, they contribute as they value the work we do together.

Despite the continuing the Covid-19 pandemic, donations totalled £27,950 from 45 member charities and, although we continued to waive donations to all member charities with an income of less than £500,000, membership donations for 2021/22 exceeded those of 2020/21.

Individual donations

Donations are welcome from any individuals or organisations who recognise the value of our contribution to supporting people with rare and less common cancers.

During the financial year 2021-22, Cancer52 received almost £19,000 from a variety of platforms and individuals.

Support from industry

In 2021–2022 we received support from Abbvie, BMS, Gilead, GSK, Ipsen, Roche, Sanofi and Takeda, who all benefited from membership of Cancer52’s Corporate Supporter Programme.

Cancer52 has a clear policy when working with the pharmaceutical industry and abides by industry guidelines.[6] Some 62.7% of our funding comes from pharmaceutical companies. This comprises support for specific projects as well as unrestricted support.

We believe all our industry partners recognise the value of dealing with an umbrella body that channels one voice for rare and less common cancers.

Working with Cancer52 offers a unique opportunity to engage with the voice of people with rare and less common cancers, and benefit from the expertise and knowledge gained through our relationships with member organisations.

14

Future plans

Cancer52 is proud of its achievements during this unprecedented year. Our major objectives prevail and we will take them forward into 2022–2023.

We will provide a strong, unified voice to promote improved diagnosis, treatment and support for those affected by rare and less common cancers so that we see an end to inequalities in diagnosis, treatment and patient outcomes experienced by those with these challenging diseases. In three years’ time, Cancer52 will:

UK wide

Leadership

Have retained its market leadership position but built its thought leadership and increased its collaborative work with fellow cancer charities and alliancess.

Be a well-resourced organisation making the voice of rare and less common cancers heard across the four nations of the UK wherever decisions are taken on the treatment and care of people with these cancers.

Alignment

Have reviewed its target audiences and brand name and, if necessary, be ready to take steps to change it.

Inequalities focus

Have retained its focus on its aim, mission and values whilst placing reducing inequalities at the heart of everything it does

cancer52.org.uk 15

The acoustics: structure and constitution

Structure and governance

Cancer52 is incorporated as a charitable company limited by guarantee and is a registered charity in England and Wales. It is governed by its Memorandum and Articles of Association, and the work, management, finances and strategy of the charity are overseen by a Board of Trustees, who are also the company directors. The Trustees who held office during the financial year and at the date of the report are set out on page 35.

Under the Articles of Association, a minimum of three trustees and a maximum of twelve trustees can be in office. At Annual General Meetings, one-third of the existing directors must retire by rotation based on the longest serving directors retiring first. Retiring directors may be re-appointed at Annual General Meetings by the vote of existing directors. New directors may only be appointed at Annual General Meetings where the notice and approval requirements set out in the Articles of Association have been satisfied.

The Board has agreed that the usual term of tenure for trustees should be a maximum of two terms of three years each (six years in total), with review and approval by the Board at the end of each term of tenure. In exceptional circumstances, and in order not to lose important or valuable skills, experience and expertise, trustees may serve for a third term of tenure, subject to the approval of the Board. Trustees do not receive remuneration for their duties.

Purpose

The charity’s purposes are set out in its Memorandum and Articles of Association as follows:

To promote and protect the health of people with rare and less common cancers by:

1. Advancing and promoting understanding, awareness, research and learning about rare and less common cancers;

2. Acting as a collective voice and advocating for the needs of individuals affected by a rare or less common cancer in order to improve diagnosis, treatment and long-term support outcomes; and

3. Supporting, representing and empowering not-for-profit organisations working in the field of rare and less common cancer.

Public benefit

Our work delivers public benefit by providing information and support to people diagnosed with, treated for or living with a rare or less common cancer through the services, interactions and collaboration that we facilitate between our members. We drive change and enhancements in the cancer system to improve outcomes for people affected by a rare or less common cancer.

16

As part of our business planning processes, we review our aims and objectives each year, which includes looking at what we have achieved in previous years, and how our activities have benefited those groups of people we were set up to help. We have referred to the Charity Commission’s general guidance on public benefit when reviewing our aims and objectives, and in planning our work for the future.

Board and management operations and structure

Board of Trustees

The Board of Trustees meets at least four times a year to review the organisation’s work, finances and services, and to agree strategic goals for the charity. Board meetings were virtual throughout 2021–2022 and invited the Chief Executive and the Operations Manager and others as appropriate.

The chair and other trustees with financial expertise also meet separately with the Chief Executive, Operations Manager, and the charity’s accountant on a quarterly basis to monitor and scrutinise the charity’s financial strategy and operations and make any necessary recommendations to the full Board of Trustees.

Recruitment and appointment of new trustees

Following the resignation of two trustees in 2020, the Board decided not to recruit and appoint new trustees during the Covid-19 pandemic. However, in Spring 2021, a schedule and criteria to recruit new trustees was implemented.

Our recruitment drive welcomed in five new Trustees, Anna Evans, Catherine Hodgson, Dr Max Brodermann, Michael Draeger and Sophie Davies. Each brought a wealth of knowledge and insight to the Board.

In March 2022, Catherine Hodgson resigned from the Board of Trustees as a result of leaving the sector to pursue other avenues. We pass our thanks to Catherine for her contribution to the Board during her time with us.

Related parties

The only related parties are considered to be the trustees and those connected with the trustees, including their close families, business and other charity interests. There have been no transactions with related parties, other than the reimbursement of reasonable travel expenses for the purposes of attendance at Board meetings and other relevant organisational activities.

Risk assessment and management

The Board of Trustees and the chief executive maintain a risk register and assess risks on an annual basis. The trustees are satisfied that the major risks to the organisation have been accurately identified and that appropriate systems and procedures for managing those risks are in place.

Safeguarding

We have a strong commitment to protecting and promoting the health, wellbeing and safety of all engaged in our work. While we are not a patient representative charity, we still adhere to good safeguarding practice. Our Safeguarding Policy is reviewed each year and is accessible on the Governance section of our website. All new staff and volunteers are required to participate in a full day safeguarding training course, provided by an external organisation.

Annual review

The Annual Review 2021–2022 was completed and disseminated, with thanks to the Board nominees Chris Walden and Helen Morement, and to external copywriter and designers.

cancer52.org.uk 17

cancer 52 the common voice for rare & less common cancers

18

Money talks: financial review 2021-2022

Financial statement

As shown in the statement of financial activities on the following pages, in the year 2021–2022:

Reserves policy

The Board of Trustees’ strategy on reserves is for the organisation to maintain sufficient funds to cover the operational running costs in the event of a major setback. This means that we aim to hold approximately six months’ annual expenditure in reserve.

At the end of the 2021–2022 financial year, our reserves stood at £110,289, which adequately covers the six months required.

The Company has taken advantage of the small companies’ exemption in preparing this report. The trustees declare that they have approved the trustees’ report (including directors’ report) above.

Signed on behalf of the charity’s trustees/directors

Signature

Jonathan Pearce

Trustee / Director

Date

Signature

Nic Puntis

Trustee / Director

Date

cancer52.org.uk 19

Independent examiner's report on the accounts

Section A Independent Examiner’s Report

Report to the
trustees/directors/
members of
On accounts for the year
ended
Set out on pages
Responsibilities and
basis of report		 Cancer 52
31stMarch 2022
07994413
Charity no.: 1174569 Company no.: 07994413
To
22
34
I report to the charity trustees on my examination of the accounts of the
Company for the year ended31st March 2022.
As the charity’s trustees of the Company (who are also the directors of the
company for the purposes of company law), you are responsible for the
preparation of the accounts in accordance with the requirements of the
Companies Act 2006 (“the 2006 Act”).
Having satisfied myself that the accounts of the Company are not required
to be audited for this year under Part 16 of the 2006 Act and are eligible for
independent examination, I report in respect of my examination of your
charity’s accounts as carried out under section 145 of the Charities Act 2011
(“the 2011 Act”). In carrying out my examination, I have followed the
Directions given by the Charity Commission (under section 145(5)(b) of the
2011 Act.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed: Date: 21[st] July 2022

20

Name: Jason Dennis
Relevant professional AAT - Association of Accounting Technicians
qualification(s) or body ATT – Association of Taxation Technicians
(if any):
Address: 31 Clover Way, Paddock Wood, Tonbridge, Kent TN12 6BQ
Section B Disclosure
Only complete if the examiner needs to highlight material matters of concern
(see CC32, Independent examination of charity accounts: directions and
guidance for examiners).
Give here brief details of
any items that the
examiner wishes to
disclose.

cancer52.org.uk 21

Section A

Statement of financial activities (including summary income and expenditure account)

Guidance Note
S01
S07
Expenditure (Notes 4)
Expenditure on:
S08
S09
S11
S12
S13
Tax payable
S14
S15
Net gains/(losses) on investments
S16
S17
Extraordinary items
S18
S19
S20
Other gains/(losses)
S21
S22
Reconciliation of
funds:
S23
S24
Total funds brought forward
Gains and losses on revaluation of fixed assets for the charity’s own
use
Charitable activities
Total funds carried forward
Total
Net income/(expenditure) after tax before
investment gains/(losses)
Net income/(expenditure)
Transfers between funds
Net movement in funds
Total
Recommended categories by activity
Income (Note 3)
Income and endowments from:
Donations and legacies
Other recognised gains/(losses):
Net income/(expenditure) before tax for the
reporting period
Raising funds
Other		 Unrestricted
funds
Restricted
income funds
Endowment
funds
Total funds
Prior year
funds
£
£
£
£
£
F01
F02
F03
F04
F05		 Unrestricted
funds
Restricted
income funds
Endowment
funds
Total funds
Prior year
funds
£
£
£
£
£
F01
F02
F03
F04
F05		 Unrestricted
funds
Restricted
income funds
Endowment
funds
Total funds
Prior year
funds
£
£
£
£
£
F01
F02
F03
F04
F05		 Unrestricted
funds
Restricted
income funds
Endowment
funds
Total funds
Prior year
funds
£
£
£
£
£
F01
F02
F03
F04
F05		 Unrestricted
funds
Restricted
income funds
Endowment
funds
Total funds
Prior year
funds
£
£
£
£
£
F01
F02
F03
F04
F05
144,709 - - 144,709 175,695
144,709 - - 144,709 175,695
- - - - 1,125
148,750 - - 148,750 123,103
2,400 - - 2,400 1,800
151,150 - - 151,150 126,028
(6,441) - - (6,441) 49,667
- - - - -
(6,441) - - (6,441) 49,667
- - - - -
(6,441) - - (6,441) 49,667
- - - - -
- - - - -
- - - - -
- - - - -
(6,441) - - (6,441) 49,667
116,730 - - 116,730 67,063
110,289 - - 110,289 116,730

22

Charity Number 1174569 Company Reg No 07994413

For the year ended 31 March 2022

Cancer52

Section B

Balance sheet (as at 31st March 2021)

Guidance Note
Current assets
Cash at bank and in hand (Note 24)
B09
Total current assets
B10
Creditors: amounts falling due within
one year (Note 20)
B11
Net current assets/(liabilities)
B12
Total assets less current liabilities
B13
Total net assets or liabilities
B16
Funds of the Charity
Endowment funds (Note 27)
B17
Restricted income funds (Note 27)
B18
Unrestricted funds
B19
Revaluation reserve
B20
Fair value reserve
B21
Total funds
B22		 Unrestricted
funds
£		 Restricted
income
funds
£		 Endowment
funds
Total this
year
£
£		 Endowment
funds
Total this
year
£
£		 Total last
year
£
135,949 - - 135,949 118,530
135,949 - - 135,949 118,530
25,660 - - 25,660 1,800
110,289 - - 110,289 116,730
110,289 - - 110,289 116,730
110,289 - - 110,289 116,730
- - -
- -
110,289 - 110,289 116,730
-
110,289 - - 110,289 116,730

The company was entitled to exemption from audit under s477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to small companies subject to the small companies regime and in accordance with FRS102 SORP.

Signed by one or two trustees/directors on behalf of all the
trustees/directors
Signature of director authenticating accounts being sent to Companies
House		 Print Name Date of
approval
dd/mm/yyyy
Jonathan Pearce
Nic Puntis
Signature Date
dd/mm/yyyy
Jonathan Pearce
Print name

23

Cancer52 Charity Number 1174569 Company Reg No 07994413

For the year ended 31 March 2022

Section C

Notes to the accounts

NOTE 1: Basis of preparation

This section should be completed by all charities .

1.1 Basis of accounting

These accounts have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant note(s) to these accounts.

The accounts have been prepared in accordance with:

the Statement of Recommended Practice: Accounting and Reporting by Charities preparing • and with ü their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014 the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS • and with ü 102)

The charity constitutes a public benefit entity as defined by FRS 102.*

ü

1.2 Going concern

If there are material uncertainties related to events or conditions that cast significant doubt on the charity's ability to continue as a going concern, please provide the following details or state "Not applicable", if appropriate:

An explanation as to those factors that support the Not applicable conclusion that the charity is a going concern; Disclosure of any uncertainties that make the Not applicable going concern assumption doubtful; Where accounts are not prepared on a going Not applicable concern basis, please disclose this fact together with the basis on which the trustees prepared the accounts and the reason why the charity is not regarded as a going concern.

1.3 Change of accounting policy

The accounts present a true and fair view and no changes have been made to the accounting policies adopted in note { }.

Yes ü * -Tick as appropriate No

24

Charity Number 1174569 Company Reg No 07994413

For the year ended 31 March 2022

Cancer52

Please disclose:

Please disclose:
(i) the nature of the change in accounting policy; Not applicable
(ii) the reasons why applying the new accounting policy
provides more reliable and more relevant information; and		 Not applicable
(iii) the amount of the adjustment for each line affected in
the current period, each prior period presented and the
aggregate amount of the adjustment relating to periods
before those presented, 3.44 FRS102 SORP.		 Not applicable

1.4 Changes to accounting estimates

No changes to accounting estimates have occurred in the reporting period (3.46 FRS102 SORP).

Yes
No		 ü * -Tick as appropriate

Please disclose:

Please disclose:
(i) the nature of any changes; Not applicable
(ii) the effect of the change on income and expense or
assets and liabilities for the current period; and		 Not applcable
(iii) where practicable, the effect of the change in one or
more future periods.		 Not applicable

1.5 Material prior year errors

No material prior year error have been identified in the reporting period (3.47 FRS102 SORP).

Yes
No		 ü * -Tick as appropriate

Please disclose:

Please disclose:
(i) the nature of the prior period error; Not applicable
(ii) for each prior period presented in the accounts, the
amount of the correction for each account line item
affected; and		 Not applicable
(iii) the amount of the correction at the beginning of the
earliest prior period presented in the accounts.		 Not applicable

25

Cancer52 Charity Number 1174569 Company Reg No 07994413

For the year ended 31 March 2022

NOTE 2: Accounting policies

2.1 INCOME

Recognition of income
Donated goods
In the case of performance related grants, income must only be recognised to the extent
that the charity has provided the specified goods or services as entitlement to the grant
only occurs when the performance related conditions are met (5.16 FRS 102 SORP).
Contractual income and
performance related grants
Gifts in kind for use by the charity are included in the SoFA as income from donations when
receivable.
Government grants
The charity has received government grants in the reporting period
Legacies
Tax reclaims on donations
and gifts
Legacies are included in the SOFA when receipt is probable, that is, when there has been
grant of probate, the executors have established that there are sufficient assets in the
estate and any conditions attached to the legacy are either within the control of the charity
or have been met.
This is only included in the SoFA once the charity has provided the related goods or
services or met the performance related conditions.
The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the
fair value of those gifts at the time of their receipt and they are recognised on receipt. In
the reporting period in which the stocks are distributed, they are recognised as an expense
at the carrying amount of the stocks at distribution.
Donated goods for resale are measured at fair value on initial recognition, which is the
expected proceeds from sale less the expected costs of sale, and recognised in 'Income
from other trading activities' with the corresponding stock recognised in the balance sheet.
On its sale the value of stock is charged against 'Income from other trading activities' and
the proceeds from sale are also recognised as 'Income from other trading activities'.
Goods donated for on-going use by the charity are recognised as tangible fixed assets and
included in the SoFA as incoming resources when receivable.
Donated goods are measured at fair value (the amount for which the asset could be
exchanged) unless impractical to do so.
Offsetting
Grants and donations
Gift Aid receivable is included in income when there is a valid declaration from the donor.
Any Gift Aid amount recovered on a donation is considered to be part of that gift and is
treated as an addition to the same fund as the initial donation unless the donor or the
terms of the appeal have specified otherwise.
There has been no offsetting of assets and liabilities, or income and expenses, unless
required or permitted by the FRS 102 SORP or FRS 102.
These are included in the Statement of Financial Activities (SoFA) when:
• the charity becomes entitled to the resources;
• it is more likely than not that the trustees will receive the resources;
• the monetary value can be measured with sufficient reliability.
Grants and donations are only included in the SoFA when the general income recognition
criteria are met (5.10 to 5.12 FRS102 SORP).		 Yes
No
N/a*		 Yes
No
N/a*		 Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü

26

Charity Number 1174569 Company Reg No 07994413

For the year ended 31 March 2022

Cancer52

Donated services and Donated services and facilities are included in the SOFA when received at the value of the Yes* No* N/a*
facilities gift to the charity provided the value of the gift can be measured reliably. ü
Donated services and facilities that are consumed immediately are recognised as income Yes* No* N/a*
with an equivalent amount recognised as an expense under the appropriate heading in the
SOFA.		 ü
Support costs The charity has incurred expenditure on support costs. Yes* No* N/a*
ü
Volunteer help The value of any voluntary help received is not included in the accounts but is described in
the trustees’ annual report.		 Yes* No* N/a*
ü
Income from interest, This is included in the accounts when receipt is probable and the amount receivable can be Yes* No* N/a*
royalties and dividends measured reliably. ü
Income from membership Membership subscriptions received in the nature of a gift are recognised in Donations and Yes* No* N/a*
subscriptions Legacies. ü
Membership subscriptions which gives a member the right to buy services or other benefits Yes* No* N/a*
are recognised as income earned from the provision of goods and services as income from
charitable activities. ü
Settlement of insurance
claims		 Insurance claims are only included in the SoFA when the general income recognition criteria
are met (5.10 to 5.12 FRS102 SORP) and are included as an item of other income in the
SoFA.		 Yes* No* N/a*
ü
Investment gains and This includes any realised or unrealised gains or losses on the sale of investments and any Yes* No* N/a*
losses gain or loss resulting from revaluing investments to market value at the end of the year. ü
2.2 EXPENDITURE AND LIABILITIES
Liabilities are recognised where it is more likely than not that there is a legal or constructive Yes* No* N/a*
Liability recognition obligation committing the charity to pay out resources and the amount of the obligation can
be measured with reasonable certainty.		 ü ü ü
Governance and support
costs		 Support costs have been allocated between governance costs and other support.
Governance costs comprise all costs involving public accountability of the charity and its		 Yes* No* N/a*
compliance with regulation and good practice. ü
Support costs include central functions and have been allocated to activity cost categories
on a basis consistent with the use of resources, eg allocating property costs by floor areas, Yes* No* N/a*
or per capita, staff costs by the time spent and other costs by their usage. ü
Grants with performance Where the charity gives a grant with conditions for its payment being a specific level of
conditions service or output to be provided, such grants are only recognised in the SoFA once the Yes* No* N/a*
recipient of the grant has provided the specified service or output. ü
Grants payable without Where there are no conditions attaching to the grant that enables the donor charity to
performance conditions realistically avoid the commitment, a liability for the full funding obligation must be Yes* No* N/a*
recognised. ü
Redundancy cost The charity made no redundancy payments during the reporting period. Yes* No* N/a*
ü
Deferred income No material item of deferred income has been included in the accounts. Yes* No* N/a*
ü
Creditors The charity has creditors which are measured at settlement amounts less any trade
discounts		 Yes* No*
ü		 N/a*
Provisions for liabilities A liability is measured on recognition at its historical cost and then subsequently measured
at the best estimate of the amount required to settle the obligation at the reporting date		 Yes* No* N/a*
ü
Basic financial instruments The charity accounts for basic financial instruments on initial recognition as per paragraph
10.7 FRS102 SORP. Subsequent measurement is as per paragraphs 11.17 to 11.19,
FRS102 SORP.		 Yes* No* N/a*
ü

27

Charity Number 1174569 Company Reg No 07994413

For the year ended 31 March 2022

Cancer52

2.3 ASSETS
The charity has investments which it holds for resale or pending their sale and cash and
cash equivalents with a maturity date less than one year. These include cash on deposit
and cash equivalents with a maturity of loss than one year held for investment purposes
rather than to meet short-term cash commitments as they fall due.
Investments
Fixed asset investments in quoted shares, traded bonds and similar investments are valued
at initially at cost and subsequently at fair value (their market value) at the year end. The
same treatment is applied to unlisted investments unless fair value cannot be measured
reliably in which case it is measured at cost less impairment.
Current asset investments
These are capitalised if they can be used for more than one year, and cost at least
Heritage assets
Stocks and work in
progress
Debtors
They are valued at cost.
Tangible fixed assets for
use by charity
The depreciation rates and methods used are disclosed in note 14.
Intangible fixed assets
Investments held for resale or pending their sale and cash and cash equivalents with a
maturity date of less than 1 year are treated as current asset investments
They are valued at cost.
They are valued at cost.
The charity has intangible fixed assets, that is, non-monetary assets that do not have
physical substance but are identifiable and are controlled by the charity through custody or
legal rights. The amortisation rates and methods used are disclosed in note 15.
The charity has heritage assets, that is, non-monetary assets with historic, artistic, scientific,
technological, geophysical or environmental qualities that are held and maintained
principally for their contribution to knowledge and culture. The depreciation rates and
methods used as disclosed in note 16.
Stocks held for sale as part of non-charitable trade are measured at the lower or cost or net
realisable value.
Goods or services provided as part of a charitable activity are measured at net realisable
value based on the service potential provided by items of stock.
Debtors (including trade debtors and loans receivable) are measured on initial recognition at
settlement amount after any trade discounts or amount advanced by the charity.
Subsequently, they are measured at the cash or other consideration expected to be
received.
Work in progress is valued at cost less any foreseeable loss that is likely to occur on the
contract.
They are valued at fair value except where they qualify as basic financial instruments.
£2,500
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü
Yes
No
N/a*
ü

POLICIES ADOPTED ADDITIONAL TO OR DIFFERENT FROM THOSE ABOVE

NOTE 3: Income

Donations
Donations and gifts
Membership subscriptions and sponsorships
which are in substance donations
Total
Analysis of income
TOTAL INCOME		 Analysis of income Unrestricted
funds
Restricted
income
funds
Endowment
funds
Total funds
Prior year
£
£
114,755
- -114,755 150,409
29,954
- -29,954 25,286
144,709
- -144,709175,695
144,709
- -144,709 175,695		 Unrestricted
funds
Restricted
income
funds
Endowment
funds
Total funds
Prior year
£
£
114,755
- -114,755 150,409
29,954
- -29,954 25,286
144,709
- -144,709175,695
144,709
- -144,709 175,695		 Unrestricted
funds
Restricted
income
funds
Endowment
funds
Total funds
Prior year
£
£
114,755
- -114,755 150,409
29,954
- -29,954 25,286
144,709
- -144,709175,695
144,709
- -144,709 175,695		 Unrestricted
funds
Restricted
income
funds
Endowment
funds
Total funds
Prior year
£
£
114,755
- -114,755 150,409
29,954
- -29,954 25,286
144,709
- -144,709175,695
144,709
- -144,709 175,695
Donations and gifts 114,755 - - 114,755
Membership subscriptions and sponsorships
which are in substance donations		 29,954 - - 29,954
Total 144,709 - - 144,709
144,709 - - 144,709

28

Cancer52 Charity Number 1174569 Company Reg No 07994413

For the year ended 31 March 2022

NOTE 4: Expenditure

Analysis
Expenditure on raising funds		 Analysis
Expenditure on raising funds		 Unrestricted
funds
Restricted
income funds
Endowment
funds
Total funds
Unrestricted
funds
Restricted
income
funds
Endowment
funds
Total funds
£
£
This year
Last year		 Unrestricted
funds
Restricted
income funds
Endowment
funds
Total funds
Unrestricted
funds
Restricted
income
funds
Endowment
funds
Total funds
£
£
This year
Last year		 Unrestricted
funds
Restricted
income funds
Endowment
funds
Total funds
Unrestricted
funds
Restricted
income
funds
Endowment
funds
Total funds
£
£
This year
Last year		 Unrestricted
funds
Restricted
income funds
Endowment
funds
Total funds
Unrestricted
funds
Restricted
income
funds
Endowment
funds
Total funds
£
£
This year
Last year		 Unrestricted
funds
Restricted
income funds
Endowment
funds
Total funds
Unrestricted
funds
Restricted
income
funds
Endowment
funds
Total funds
£
£
This year
Last year		 Unrestricted
funds
Restricted
income funds
Endowment
funds
Total funds
Unrestricted
funds
Restricted
income
funds
Endowment
funds
Total funds
£
£
This year
Last year		 Unrestricted
funds
Restricted
income funds
Endowment
funds
Total funds
Unrestricted
funds
Restricted
income
funds
Endowment
funds
Total funds
£
£
This year
Last year		 Unrestricted
funds
Restricted
income funds
Endowment
funds
Total funds
Unrestricted
funds
Restricted
income
funds
Endowment
funds
Total funds
£
£
This year
Last year

Fundraising consultants		 - - - - 1,125 - - 1,125
Total expenditure on raising funds - - - - 1,125 - - 1,125
Expenditure on charitable activities:
All Member Meetings, Steering Group Meetings, Room
Hire, Venue Costs		 600 - - 600 - - - -
Patient Voice Film - - - - - 1,483 - 1,483
Covid Impact Report - - - - - 800 - 800
Shared Cancer Planning Project - - - - - 600 - 600
Patient Survey Project 7,326 - - 7,326 - 9,600 - 9,600
Pfizer Project Support 10,020 - - 10,020 - 6,520 - 6,520
Impact Reporting and Annual Review
Telephone		 1,505 - - 1,505 - 5,520 - 5,520
74 - - 74 - - - -
IT and Computer running expenses 443 - - 443 - 96 - 96
Policy consultants - Policy Support 19,605 - - 19,605 - 18,140 - 18,140
Policy Report 2,175 - - 2,175 - - - -
Subscriptions 1,384 - - 1,384 - 933 - 933
Secretarial expenses 31,855 - - 31,855 - 29,713 - 29,713
Insurance 556 - - 556 533 - - 533
Management and Administration 4,000 - - 4,000 34,806 3,958 - 38,764
Salaries and Employers NI and Pensions 66,060 - - 66,060 - - - -
Communications and PR 2,000 - - 2,000 9,691 - - 9,691
Bank and credit fees 216 - - 216 216 - - 216
Trustees/Directors Travel 162 - - 162 - - - -
Trustee Recruitment costs and expenses 319 - 319 494 494
Non-Trustee Recruitment 450 - - 450 - - - -
Total expenditure on charitable activities 148,750 - - 148,750 45,246 77,857 - 123,103
Other
Independent Examiner 2,400 - - 2,400 1,800 - - 1,800

Total other expenditure
TOTAL EXPENDITURE		 2,400 - - 2,400 1,800 - - 1,800
151,150 - - 151,150 48,171 77,857 - 126,028

NOTE 5: Details of certain types of expenditure

Note 5.1 Fees for examination of the accounts

Please provide details of the amount paid for any statutory external scrutiny of accounts and other services provided by your independent examiner. If nothing was paid please enter '0' in the appropriate box(es).

enter '0' in the appropriate box(es).
Independent examiner’s fees This year
£		 Last year
£
2,400 1,800

29

Cancer52 Charity Number 1174569 Company Reg No 07994413

For the year ended 31 March 2022

NOTE 6: Paid Employees

Please complete this note if the charity has any employees (transactions with Trustees dealt with in Note 28)

6.1 Staff Costs

This year
Last year
£
£
60,000 -
3,060 -
3,000
- -
66,060 -
Salaries and wages
Social security costs
Pension costs (defined contribution scheme)
Other employee benefits
Total staff costs
Please give details of the number of employees whose total employeebenefits (excluding employer pension costs)
No employees received employee benefits (excluding employer		 This year
Last year
£
£
60,000 -
3,060 -
3,000
- -
66,060 -
Salaries and wages
Social security costs
Pension costs (defined contribution scheme)
Other employee benefits
Total staff costs
Please give details of the number of employees whose total employeebenefits (excluding employer pension costs)
No employees received employee benefits (excluding employer		 This year
£		 Last year
£
60,000 -
3,060 -
3,000
- -
66,060 -
Band Number of employees
Thisyear Lastyear
£60,000 to £69,999 1 -
Fundraising
Charitable Activities
Governance
Other
Total
Please provide the total amount paid to key management personnel
6.2 Average head count in the year
The parts of the charity in which the
employees work
Thisyear Lastyear
£ £
60,000 -
This year
Number		 Last year
Number
Fundraising - -
Charitable Activities - -
Governance 1 -
Other - -
Total 1 -

NOTE 7: Creditors and accruals

Please complete this note if the charity has any creditors or accruals.

7.1 Analysis of creditors

Accruals and deferred income
Other creditors
Total		 Amounts falling due within
one year		 Amounts falling due within
one year		 Amounts falling due after
more than one year		 Amounts falling due after
more than one year
This year
£		 Last year
£		 This year
£		 Last year
£
25,290 1,800 - -
370 - - -
25,660 1,800 - -

30

Charity Number 1174569 Company Reg No 07994413

For the year ended 31 March 2022

Cancer52

NOTE 8: Cash at bank and in hand

Cash at bank and on hand Total

This year
£		 Last year
£
135,949 118,530
135,949 118,530

NOTE 9: Fair value of assets and liabilities

9.1 Please provide details of the charity's
exposure to credit risk (the risk of incurring a
loss due to a debtor not paying what is owed)
, liquidity risk (the risk of not being able to
meet short term financial demands) and
market risk (the risk that the value of an
investment will fall due to changes in the
market) arising from financial instruments to
which the charity is exposed at the end of the
reporting period and explain how the charity
manages those risks.
9.2 Please give details of the amount of
change in the fair value of basic financial
instruments (debtors, creditors, investments
(see section 11, FRS 102 SORP)) measured at
fair value through the SoFA that is attributable
to changes in credit risk.		 This year
Last year		 This year
Last year
Credit risk is low due to income being in the form
of donations. Cash is the only investment so
market risk is low on investment values falling.
Liquidity risk is low as costs are managed in
relation to income received.		 Credit risk is low due to income being in the form of
donations. Cash is the only investment so market
risk is low on investment values falling. Liquidity
risk is low as costs are managed in relation to
income received.


Not applicable		 Not applicable

31

Cancer52 Charity Number 1174569 Company Reg No 07994413

For the year ended 31 March 2022

NOTE 10: Charity funds

y funds
10.1 Details of material funds held and movements during the CURRENT reporting period
Please give details of the movements of material individual funds in the reporting period together with a balancing figure for 'Other funds' (which should include revaluation
reserve and fair value reserve, if applicable). The 'Total funds' figure below should reconcile to 'Total funds' in the balance sheet.
* Key: PE - permanent endowment funds; EE - expendable endowment funds; R - restricted income funds, including special trusts, of the charity; and U - unrestricted funds		 Fund
balances
carried
forward
£		 110,289 110,289 Yes
No		 Fund balances carried forward include assets and liabilities denominated in a foreign currency
ü
ü
Gains and
losses
£		 - -
Transfers
£		 - -
Expenditure
£		 (151,150) (151,150)
Income
£		 144,709 144,709
Fund
balances
brought
forward
£		 116,730 116,730
Purpose and Restrictions General all purpose no restrictions Total Funds as per balance sheet If yes, please state the basis on which the assets and/or liabilities have been translated into
sterling (or the currency in which the accounts are drawn up).
Type PE, EE R
**or UR ***		 UR
Fund names General Fund

32

Charity Number 1174569 Company Reg No 07994413

For the year ended 31 March 2022

Cancer52

10.2 Details of material funds held and movements during the PREVIOUS reporting period Please give details of the movements of material individual funds in the reporting period together with a balancing figure for 'Other funds' (which should include revaluation reserve and fair value reserve, if applicable). The 'Total funds' figure below should reconcile to 'Total funds' in the balance sheet. * Key: PE - permanent endowment funds; EE - expendable endowment funds; R - restricted income funds, including special trusts, of the charity; and U - unrestricted funds Fund
Fund		 balances
brought
forward
Income
Expenditure
Transfers
Gains and
losses
balances
carried
forward
Type PE, EE R
or UR
Purpose and Restrictions*		 £
£
£
£
£
£
Fund names		 General Fund
UR
General all purpose no restrictions
67,063 97,838
(48,171) - - 116,730		 Covid-19 Restricted Fund
R
Restricted to Core Charitable Expenditure
- 77,857
(77,857) - - -		 67,063 175,695
(126,028) - - 116,730
Total Funds as per balance sheet		 Yes
No		 Fund balances carried forward include assets and liabilities denominated in a foreign currency
ü
ü

33

Cancer52 Charity Number 1174569 Company Reg No 07994413

For the year ended 31 March 2022

NOTE 11: Transactions with trustees and relates parties

If the charity has any transactions with related parties (other than the trustee expenses explained in guidance notes) details of such transactions should be provided in this note. If there are no transactions to report, please enter “True” in the box or "False" if there are transactions to report.

11.1 Trustee remuneration and benefits

This year

None of the trustees have been paid any remuneration or received any other benefits from an employment TRUE with their charity or a related entity (True or False)

11.2 Trustees' expenses

If the charity has paid trustees expenses for fulfilling their duties, details of such transactions should be provided in this note. If there are no transactions to report, please enter “True” in the box below. If there are transactions to report, please enter "False".

No trustee expenses have been incurred (True or False) TRUE
Type of expenses reimbursed This year Last year
£ £
Travel - -
TOTAL - -
Please provide the number of trustees reimbursed for expenses or who had
expenses paid by the charity
0 0

11.3 Transaction(s) with related parties

Please give details of any transaction undertaken by (or on behalf of) the charity in which a related party has a material interest, including where funds have been held as agent for related parties. If there are no such transactions, please enter 'true' in the box provided.

This year

There have been no related party transactions in the reporting period (True or False) TRUE
Last year
There have been no related party transactions in the reporting period (True or False)
TRUE

34

Charity Number 1174569 Company Reg No 07994413

For the year ended 31 March 2022

Cancer52

Administrative details

TRUSTEES

EXECUTIVE OFFICERS

Baroness Morgan of Drefelin President Jane Lyons Chief executive Jonathan Pearce Company secretary

Jonathan Pearce, Chair Helen Morement Rebecca Porta Nic Puntis Christopher Walden Anna Evans Dr Max Brodermann Michael Draeger Sophie Davies

REGISTERED OFFICE

c/o Teenage Cancer Trust 3rd Floor, 93 Newman Street, London W1T 3EZ

WEBSITE

www.cancer52.org.uk

BANKERS

Co-operative Bank

cancer52.org.uk 35

References

1 National Cancer Registration and Analysis Service (NCRAS) by Public Health England figures. May 2019

https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk#heading-Zero.

https://www.smartinsights.com/email-marketing/email-communications-strategy/statistics-sources-for-email-marketing/#q4

Available: https://www.cancer52.org.uk/single-post/health-and-social-care-committee-report-on-cancer-services

10 10-Year Cancer Plan. Call for Evidence. Available: https://www.gov.uk/government/consultations/10-year-cancer-plan-call-for-evidence 11 10-Year Cancer Plan. Cancer52 response to the Call for Evidence. Available:

https://www.cancer52.org.uk/single-post/10-year-cancer-plan-cancer52-response-to-the-call-for-evidence

15 Policy on Working with the Pharmaceutical & Healthcare Industry. Microsoft Word - Cancer52 Pharmaco Policy March 2020 Amended after March Board FINAL

36

List of charity members 2021/22

ACLT (African Caribbean Leukaemia Trust) www.aclt.org

Brain Tumour Research

www.braintumourresearch.org

Act for Cancer www.actforcancer.org.uk

Brain Tumour Research Campaign (Wayahead) www.btrc-charity.org

Action Against Heartburn www.actionagainstheartburn.org.uk

Brainstrust www.brainstrust.org.uk

Action Bladder Cancer UK www.actionbladdercanceruk.org

British Lymphology Society (BLS) www.thebls.com

Action Kidney Cancer www.kcsn.org.uk

Action on Womb Cancer www.actiononwombcancer.org.uk

British Thyroid Foundation (BTF-thyroid) www.btf-thyroid.org

Butterfly Thyroid Cancer Trust (BTCT) www.butterfly.org.uk

Alike www.alike.org.uk

Cancer Laryngectomee Trust www.cancerlt.org

ALK Positive Lung Cancer www.alkpositive.org.uk

AMMF – The Cholangiocarcinoma Charity www.ammf.org.uk

Anthony Nolan www.anthonynolan.org

Association for Multiple Endocrine Neoplasia Disorders (AMEND) www.amend.org.uk

Cancer of Unknown Primary (CUP) Foundation – Jo’s friends www.cupfoundjo.org

Childhood Eye Cancer Trust (CHECT) www.chect.org.uk

Children’s Cancer and Leukaemia Group (CCLG) www.cclg.org.uk

Chordoma UK www.chordoma-uk.org

Baggy Trousers UK www.baggytrousersuk.org

Chris Lucas Trust www.chrislucastrust.com

Balls to Cancer www.ballstocancer.co.uk

Chronic Myeloid Leukaemia (CML) Support Group UK www.cmlsupport.org.uk

Barrett’s Oesophagus UK www.barrettscampaign.org.uk

CLL Support Association www.cllsupport.org.uk

Blood Cancer UK www.bloodcancer.org.uk

Debbie Fund www.debbiefund.org

Bone Cancer Research Trust www.bcrt.org.uk

DKMS www.dkms.org.uk

Bowel Research UK www.bowelresearchuk.org

EHE Rare Cancer Charity (UK) www.ehercc.org.uk

cancer52.org.uk 37

Ellen MacArthur Cancer Trust www.ellenmacarthurcancertrust.org

Fight Bladder Cancer www.fightbladdercancer.co.uk

GIST Cancer UK www.gistcancer.org.uk

Grace Kelly Childhood Cancer Trust www.gkcct.org

GUTS Charity www.gutscharity.org.uk

Heartburn Cancer UK www.heartburncanceruk.org

HLRCC Family Alliance www.hlrccinfo.org

ICPV Independent Cancer Patients’ Voice www.icpv.org.uk

International Brain Tumour Alliance (IBTA) www.theibta.org

It’s In The Bag Cancer Support Ltd www.itsinthebag.org.uk

It’s on the Ball www.itsontheball.org

Jo’s Cervical Cancer Trust www.jostrust.org.uk

Kidney Cancer UK www.kcuk.org.uk

Live Through This www.livethroughthis.co.uk

Leukaemia CARE www.leukaemiacare.org.uk

Leukaemia UK www.leukaemiauk.org.uk

Lymphoedema Support Network www.lymphoedema.org

Lymphoma Action www.lymphoma-action.org.uk

MDS (Myelodysplastic Syndromes) UK Patient Support Group www.mdspatientsupport.org.uk

Melanoma Focus www.melanomafocus.com

Melanoma UK www.melanomauk.org.uk

Mesothelioma UK www.mesothelioma.uk.com

MPN Voice www.mpnvoice.org.uk

Mummy’s Star www.mummysstar.org

Myeloma UK www.myeloma.org.uk

Neuroblastoma UK www.neuroblastoma.org.uk

Neuroendocrine Cancer UK (NCUK) www.neuroendocrinecancer.org.uk

North West Cancer Research www.nwcr.org

OcuMel UK www.ocumeluk.org

Oracle Cancer Trust www.oraclecancertrust.org

Orchid Cancer Appeal www.orchid-cancer.org.uk

Ovacome, The Ovarian Cancer Support Network www.ovacome.org.uk

Ovarian Cancer Action www.ovarian.org.uk

Pancreatic Cancer Action www.pancreaticcanceraction.org

Pancreatic Cancer UK (PCUK) www.pancreaticcancer.org.uk

Paul’s Cancer Support Centre www.pauls.org.uk

Maggie’s Cancer Caring Centres www.maggies.org

38

Pelvic Radiation Disease Association (PRDA) www.prda.org.uk

Penny Brohn UK www.pennybrohn.org.uk

PLANETS www.planetscharity.org

Pseudomyxoma Survivor www.pseudomyxomasurvivor.org

Salivary Gland Cancer UK www.salivaryglandcancer.uk

Sarcoma UK www.sarcoma.org.uk

Shine Cancer Support www.shinecancersupport.org

Solving Kids’ Cancer www.solvingkidscancer.org.uk

Target Ovarian Cancer www.targetovariancancer.org.uk

Team Margot Foundation www.teammargot.com

Teenage Cancer Trust (TCT) www.teenagecancertrust.org

The Brain Tumour Charity www.thebraintumourcharity.org

The Charley Ashton Foundation www.thecharleyashtonfoundation

The Eve Appeal www.eveappeal.org.uk

The Mavis Nye Foundation www.mavisnyefoundation.com

ThymicUK www.thymicuk.org

Thyroid Cancer Support Group Wales www.thyroidsupportwales.co.uk

Tom Bowdidge Youth Cancer Foundation www.tombowdidgefoundation.org

Trekstock www.trekstock.com

UCARE www.ucare-cancer.org.uk

UK Masto www.ukmasto.org

Urostomy Association www.urostomyassociation.org.uk

VHL UK/Ireland www.vhl-uk-ireland.org

Wellbeing of Women www.wellbeingofwomen.org.uk

Wendy Gough Cancer Awareness Foundation www.wgcaf.com

WMUK www.wmuk.org.uk

Womb Cancer Info www.wombcancerinfo.wixsite.com/home

Womb Cancer Support UK www.wombcancersupportuk.weebly.com

Yorkshire Cancer Community www.yorkshirecancercommunity.co.uk

Young Lives Vs. Cancer www.younglivesvscancer.org.uk

The Myrovlytis Trust www.myrovlytistrust.org

The Northern Ireland Rare Disease Partnership www.nirdp.org.uk

The Robin Cancer Trust www.therobincancertrust.org

The Urology Foundation www.theurologyfoundation.org

cancer52.org.uk 39

cancer 52 the common voice for rare & less common cancers

Cancer52 is registered as a charity in England and Wales, Charity No. 1174569 and as a company limited by guarantee in England and Wales, Company No. 07994413

If we work together we can make as much noise as the big four

cancer52.org.uk

email: info@cancer52.org.uk